Despite some negative news, mainly related to reimbursement issues and excess stock booking, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) recently gained solid momentum due to a...
Keep Reading →
July 28 - News
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Keep Reading →
July 24 - News
Medical device stocks are an excellent place to be if you are still wary of the macro-economy.
Keep Reading →
July 23 - News
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic...
Keep Reading →
July 18 - News
It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market.
Keep Reading →
July 10 - News
This year, the North American players in the biotechnology industry are expected to spend $15 billion.
Keep Reading →
July 5 - News
After all of the hype and hoopla over Pfizer Inc.
Keep Reading →
July 3 - News
Elan Corporation, plc (ADR) (NYSE:ELN)'s board unanimously rebuffed a $6.7 billion takeover offer from Royalty Pharma in early June and hired Citigroup Inc.
Keep Reading →
July 2 - News
According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion...
Keep Reading →
July 2 - News
Proxy fights are like the demolition derby of the investment world.
Keep Reading →
June 27 - News
Under normal circumstances, the markets would sell off on news that the U.S. Commerce Department made a downward revision to its final first-quarter GDP growth figure.
Keep Reading →
June 26 - News
Dividend stocks are hard to come by in the biotech space.
Keep Reading →
June 26 - News
The U.S. stock market is down around 6%, Treasuries are getting crushed, bond funds are down, and gold is down.
Keep Reading →
June 25 - News
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Keep Reading →
June 25 - News
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Keep Reading →
June 24 - News
Recently Elan Corporation, plc (ADR) (NYSE:ELN)'s shareholders voted against management's proposal to invest $1 billion in Theravance Inc (NASDAQ:THRX), a deal which a fellow...
Keep Reading →
June 18 - News
Elan Corporation, plc (ADR) (NYSE:ELN) has been in the news over the past few months because of a hotly contested battle with Royalty Pharma. The battle began on Feb.
Keep Reading →
June 18 - News
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Keep Reading →
June 17 - Stock Analysis
After a year-long dream run, Biogen Idec Inc. (NASDAQ:BIIB) lost 5.25% in the week ended Friday, June 7.
Keep Reading →
June 17 - News
Biotechnology's a volatile sector that can intimidate many investors, but it's also a landscape of stocks that can reward portfolios with giant gains.
Keep Reading →
June 17 - News
It's been a tough week for equities.
Keep Reading →
June 14 - News
With one product already on the market, one recently approved and four more in various stages of clinical development, Biogen Idec Inc.
Keep Reading →
June 12 - News
To the untrained eye, there are many facts and figures for Biogen Idec Inc. (NASDAQ:BIIB) investors to track, but it's useful to be aware of a company's short sellers.
Keep Reading →
June 6 - News
If you somehow glossed over the title of this article, then skipped this paragraph and simply read about the following three stocks without any context, you might think that today...
Keep Reading →
June 4 - News
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
June 3 - News
You have plenty of choices of where to invest your portfolio.
Keep Reading →
May 31 - News
To most traders, hedge funds are assumed to be worthless, outdated financial tools of years past.
Keep Reading →
May 28 - News
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
May 24 - News
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Keep Reading →
May 24 - News
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Keep Reading →
May 23 - News
Combining nice dividends with a growing industry that comprises roughly one-fifth of the nation's GDP should make for an attractive stock -- in theory.
Keep Reading →
May 15 - News
Bio stocks can be a gamble.
Keep Reading →
May 1 - News
With roughly $2.5bn in assets under management, Navellier & Associates is a team of about twelve investment professionals that use quantitative and fundamental analysis to employ...
Keep Reading →
April 29 - Hedge Funds
Rising biotech stars Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Gilead Sciences, Inc.
Keep Reading →
April 29 - News
If you thought that the great run so far in 2013 was over for Biogen Idec Inc. (NASDAQ:BIIB), think again.
Keep Reading →
April 25 - News
If there's one health-care stock every investor knows by name, it's Johnson & Johnson (NYSE:JNJ).
Keep Reading →
April 25 - News
I don't know about you, but I'm pretty stoked for the NFL draft this Thursday.
Keep Reading →
April 22 - News
If you haven't noticed, it's earnings season once again! Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those...
Keep Reading →
April 21 - News
After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corporation, plc (ADR) (...
Keep Reading →
April 18 - News
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 17 - News
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Keep Reading →
April 16 - Stock Analysis
Arena Pharmaceuticals, Inc.
Keep Reading →
April 15 - News
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Keep Reading →
April 7 - News
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 7 - News
With the SPDR S&P Biotech (ETF) (NYSEARCA:XBI) Index up 25% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector...
Keep Reading →
March 31 - News
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Keep Reading →
March 28 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News